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Reactive oxygen species (ROS) can initiate cancer, but oxidant generation in tumors leaves them vulnerable
to further stresses. In this issue ofCancer Cell, Harris and colleagues show that augmenting oxidant stress in
normal cells limits tumor initiation and progression. Hence, strategic targeting of antioxidant systems may
undermine survival of new tumor cells.Low levels of reactive oxygen species
(ROS) can act as cellular signaling mes-
sengers by reversibly oxidizing protein
thiol groups, thereby modifying protein
structure and function. Higher levels of
ROS disrupt cellular processes by non-
specifically attacking proteins, lipids, and
DNA. Cellular antioxidant systems help to
limit the damagebydetoxifyingROS,while
other antioxidant systems act by reversing
oxidant-mediatedmodifications (Figure 1).
Oxidant stress and redox signaling have
been implicated in the genesis of cancer,
and ROS can affect the phenotypic
behavior of cancer cells and their respon-
siveness to therapeutic interventions (Sab-
harwal and Schumacker, 2014). Oxidative
damage to DNA can certainly promote
cancer-causing mutations. Oncogenic
transformation of fibroblasts is associated
with increases in basal levels of oxidative
signaling that may drive proliferation and
promote further mutations. The impor-
tanceofROS indrivingcancerprogression
was demonstrated by Gao et al. (2007),
who administered the antioxidant N-acetyl
cysteine (NAC) to mice carrying tumor
xenografts. They observed a decrease in
tumor growth that was traced to a redox-
mediated attenuation in levels of the
transcription factor, Hypoxia-Inducible
Factor-1 (HIF-1) (Gao et al., 2007). Thus,
HIF-1 activation by oxidant signals en-
hances the survival and progression
of tumors by upregulating genes regu-
lating glycolysis, angiogenesis, and cell
metabolism.
The idea that ROS-driven oxidant stress
initiates cancer and drives progression
has fueled a long-standing interest in the
use of antioxidants to prevent cancer.
Yet a large-scale prospective randomized
clinical trial detected an increase in pros-156 Cancer Cell 27, February 9, 2015 ª2015tate cancer in healthy men taking vitamin
E supplements, suggesting that some
oxidant stress may act as a brake on
tumorigenesis. Moreover, in K-ras and B-
raf-driven genetic models of lung cancer,
Sayin et al. (2014) found that NAC and
vitamin E increased tumor cell proliferation
by attenuating ROS, DNA damage, and
p53 expression. These findings suggest
that increases in ROS generation that
develop as a cell becomes cancerous
represent a potentially toxic byproduct of
metabolic reprogramming and antioxidant
defenses—or exogenous antioxidants—
may enhance survival/progression by pro-
tecting the cell against the antiproliferative
effects of those oxidant stresses. The in-
creases in oxidant stress that develop in
newly formed tumor cells may render
them vulnerable to therapeutic interven-
tions that act by further augmenting
oxidant generation (Trachootham et al.,
2006; Schumacker, 2006). In that sense,
tumor cells engage in a deadly dance
where some oxidants contribute to muta-
tion and growth while excessive stress
slows proliferation and threatens survival.
In this issue of Cancer Cell, Harris et al.
(2015) provide important new insight into
this complex field. Using a combination
of genetic and pharmacological tools
to disrupt redox homeostasis, they as-
sessed the consequences in terms of
tumor initiation and progression. Their
study focuses on glutathione (GSH), a tri-
peptide that plays a key role in antioxidant
defenses. GSH synthesis requires L-
cysteine, L-glycine, and L-glutamic acid
and involves an enzyme complex (gluta-
mate cysteine ligase, GSL) consisting of
catalytic (GCLC) and amplifier (GCLM)
subunits. While GSH itself can scavenge
ROS, its primary function is to support en-Elsevier Inc.zymes that directly scavenge H2O2 or lipid
hydroperoxides. Harris et al. (2015) em-
ployed oncogene-inducedmurinemodels
of mammary cancer (MMTV-PyMT) in
a genetic background lacking GCLM
(Gclm/). Deficiency in GCLM led to a
75% decrease in GSH levels, shifting the
cells to a state of chronic oxidant stress.
The effects on subsequent tumor devel-
opment were then assessed.
Interestingly, increased oxidant stress
led to fewer tumors that progressed more
slowly than those in mice with normal
GSH. This suggests that increased oxidant
stress was detrimental to the process of
tumorigenesis and progression toward
an invasive phenotype. In related experi-
ments, they used buthionine sulfoxi-
mine (BSO), an inhibitor of GSL, to
suppress GSH synthesis. When adminis-
tered continuously upon weaning, BSO
depleted GSH levels, augmented DNA
oxidation and conferredprotectionagainst
tumorigenesis in a manner that mirrored
the response in the GCLM-deficient mice.
Curiously, the effectsofBSOonDNAdam-
age and the protection were lost when
BSO was started later, after the appear-
ance of tumors. They conclude that the
oxidant stressmediated byGSH depletion
inhibited tumorigenesis because, in the
setting of oncogene-inducedROSgenera-
tion, it pushed the tumor cells over the cliff
as they emerged. They suggest that alter-
nate antioxidant mechanisms may have
protected established tumors from this
double-hit stress. Of course an alternative
possibility is that BSO did not affect DNA
oxidation or progression in the established
tumors because it was less able to access
the tumor interiors.
Interesting insight arises from their
studies of PyMT;Gclm/ primary
Figure 1. Cancer Cells Dance with the Devil ROS
Oncogenic transformation activates proliferative reprogramming pathways that generate ROS, particu-
larly H2O2. This increases cellular oxidative stress, leading to protein, lipid, and DNA oxidation. Collectively
these stresses oppose proliferation and threaten cancer cell survival. In response, cells rely on peroxire-
doxins and glutathione peroxidases to scavenge hydroperoxides and thioredoxins or glutaredoxins to
repair oxidized proteins. GSH is important for the function of some peroxidases and the protection of pro-
teins from excessive oxidation. GSH synthesis requires glutamate-cysteine ligase (GCL) consisting of
GCLC and GCLM subunits. Deletion of GCLM or inhibition of GCL by BSO depletes cellular GSH levels,
augmenting oxidant stresses. In that setting, additional stresses induced by inhibiting thioredoxin reduc-
tase or preventing uptake of cystine by the Xc- transporter pushes the oxidant stress into the toxic range.
Importantly, in the setting of depleted GSH, the cells become highly dependent on the thioredoxin system,
which is fueled by NADPH.
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Previewsmammary epithelial cells, which exhibited
oxidant stresses and decreased growth
rates that were reversed by the antioxi-
dant Trolox. The authors conclude that
decreased GSH in normal epithelial cells
suppresses growth through a mechanism
involving impaired ROS detoxification.
They also detected activation of Nuclear
Factor (erythroid-derived 2)-like factor 2
(Nrf2), a transcription factor that regulates
expression of antioxidant enzymes. Other
redox-dependent transcription factors
were probably also activated in response
to the same oxidant stimulus.
GSH synthesis is facilitated by an
amino acid transporter in the plasma
membrane termed Xc-, which exports
glutamate in exchange for cystine. Intra-
cellular cystine is then reduced to
cysteine using NADPH, making it avail-
able for protein synthesis. They found ev-
idence of increased Xc- activity, which
likely contributed to the increased expres-sion of supplementary antioxidants such
as thioredoxins.
Thioredoxins are small peptides that
repair oxidized proteins through cysteine
thiol disulfide exchange. Oxidized thiore-
doxins are reactivated by thioredoxin re-
ductases, which rely on NADPH and are
independent of GSH. Compared to cells
or mice given BSO alone, cell growth and
tumor progression were inhibited when
cells depleted of GSH were also given in-
hibitors of either the Xc- transporter or thi-
oredoxin reductase. Again, the effects of
dual inhibitionwere rescued by the antiox-
idant Trolox. These findings suggest that
tumor cells lacking GSH can still compen-
sate by upregulating the thioredoxin sys-
tem in an Xc–dependent manner.
What does this tell us about ROS in can-
cer? First, as cells become cancerous,
they activate metabolic pathways that
drive proliferation and survival. But these
pathways also generate ROS, whichCancer Cell 27strains the ability of the cells to handle
further stress. To deal with this,many can-
cer cells reprogram glycolysis to augment
flux through the pentose phosphate
pathway to assure an adequate supply of
NADPH, the proximal driver of the cellular
antioxidant machinery (Sabharwal and
Schumacker, 2014). Activation of redox-
dependent transcription factors may also
promote expression of supplementary
antioxidant systems. Harris et al. (2015)
demonstrate the importance of this stress
by showing that tumorigenesis was sup-
pressed when GSH levels were depleted
by BSO or GCLM deficiency. The ability
to reverse growth suppression with Trolox
suggests that the oncogenic pathways
themselves are critical for tumorigenesis
and progression and the ROS they
generate are a cost of doing business.
The present findings also suggest that
the excessive ROS undermine tumorigen-
esis through their effects on protein oxida-
tion rather than non-specific damage to
lipids and DNA. This conclusion is based
on their finding that thioredoxin attenu-
ated cell growth restriction in the context
of depleted GSH. Thioredoxin reverses
protein oxidation directly and also indi-
rectly by maintaining glutaredoxin func-
tion. It also supports hydroperoxide clear-
ance by reactivating peroxiredoxins, in a
GSH-independent manner. Collectively,
the studies of Harris et al. (2015) identify
important tumor vulnerabilities that could
be exploited therapeutically by inhibiting
GSH homeostasis while simultaneously
removing the safety net provided by thio-
redoxin function.REFERENCES
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